Dose-dependent effect of niceritrol on plasma lipoprotein-a

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 56, Issue 4, 1996, Pages 359-365

  Teramoto, T ^a   Yamada, N ^b   Shimano, H ^b   Oka, Y ^c   Itakura, H ^d   Saito, Y ^e   Morisaki, N ^e   Shirai, K ^f   Ishikawa, T ^g   Tada, N ^h   Ito, H ^a   Yamanouchi, T ^a   Matsushima, T ⁱ   Kawakami, M ^j   Murase, T ^k   Okubo, M ^k   Totsuka, Y ^l   Kikuchi, M ^m  

^a TEIKYO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^e CHIBA UNIVERSITY   (Japan)

^f TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^g NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^h Jikei University School of Medicine   (Japan)

ⁱ University of Tsukuba School of Medicine   (Japan)

^j JICHI MEDICAL UNIVERSITY   (Japan)

^k TORANOMON HOSPITAL   (Japan)

^l Nippon Telegraph and Telephone Corporation Medical Center Tokyo   (Japan)

^m INSTITUTE FOR ADULT DISEASES   (Japan)

more..

Author keywords

hyperlipidaemia; lipoprotein a; niceritrol; nicotinic acid

Indexed keywords

CHOLESTEROL; LIPOPROTEIN A; NICERITROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL;

EID: 8944261371     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365519609090588     Document Type: Article

References (16)

1. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. JACC 1986; 8: 1245-55.
2. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. J Am Med Assoc 1990; 264: 3013-17.
3. National Cholesterol Education Program (NCEP) Expert Panel. Summary of the second report on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). J Am Med Assoc 1993; 269: 3015-23.
4. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989; 226: 271-6.
5. 2+ quantitation of high density lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples. Clin Chem 1978; 24: 900-4.
6. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
7. Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand 1963; 59: 369-82.
8. Dahlen GH. Lipoprotein(a) in relation to atherosclerotic diseases. In: Widhalm K, Naito HK, editors. Recent aspects of diagnosis and treatment of lipoprotein disorders. Impact on prevention of atherosclerotic disease. New York: Liss, 1988: 27-36.
9. Hiraga T, Kobayashi T, Okubo M, Nakanishi K, Sugimoto T, Ohashi Y, et al. Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care 1995; 18: 241-4.
10. Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995; 91: 948-50.
11. Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995; 91: 1403-9.
12. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Goettingen risk incidence and prevalence study (GRIPS). Eur J Clin Invest 1994; 24: 444-53.
13. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara MT, Ordovas JM, Davis CE, et al. Lipoprotein(a) levels and risk of coronary heart disease in men: the lipid research clinics' coronary primary prevention trial. J Am Med Assoc 1994; 271: 999-1003.
14. Sano R, Fujino A, Kobayashi M, Shimazu H, Yahata Y, Ogyu A. Effects of ordinary dose of niceritrol on serum concentration of lipoprotein(a). Clin Rep 1991; 23: 2319-23.
15. Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). Atherosclerosis 1982; 44: 61-71.
16. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989; 80: 1313-19.